Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Vertex initiates phase Ib study for VX-950

Nov. 11, 2004

Solvay and Novozymes to develop new enzyme replacement products

Nov. 10, 2004

Adolor claims novel opioid antagonists for use in GI disorders

Nov. 9, 2004

Dynogen acquires pumosetrag from Mitsubishi Pharma

Nov. 9, 2004

spi-VEC oral hepatitis B vaccine shows promise in phase I study

Nov. 8, 2004

Sucampo and Takeda enter collaboration and license agreement for lubiprostone

Nov. 4, 2004

MD-1100 enters phase I study for IBS

Nov. 4, 2004

Axcan launches URSO Forte

Nov. 4, 2004

Pyrazine nucleosides target hepatitis C virus polymerase

Nov. 4, 2004

Partial clinical hold lifted from Stanate

Nov. 3, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....